A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
Lenti MV, Dolby V, Clark T, Hall V, Tattersall S, Fairhurst F, Kenneth C, Walker R, Kemp K, Borg-Bartolo S, Limdi JK, Taylor J, Townsend T, Subramanian S, Storey D, Assadsangabi A, Stansfield C, Smith P, Byrne D, De Silvestri A, Selinger CP.
Lenti MV, et al. Among authors: clark t.
Aliment Pharmacol Ther. 2022 Apr;55(7):856-866. doi: 10.1111/apt.16742. Epub 2021 Dec 22.
Aliment Pharmacol Ther. 2022.
PMID: 34935160
Free PMC article.